Johnson & Johnson (JNJ)
| Market Cap | 630.04B +37.9% |
| Revenue (ttm) | 97.93B +8.1% |
| Net Income | 21.04B -7.2% |
| EPS | 8.63 -7.6% |
| Shares Out | 2.41B |
| PE Ratio | 30.31 |
| Forward PE | 23.40 |
| Dividend | $5.36 (2.05%) |
| Ex-Dividend Date | Aug 25, 2026 |
| Volume | 5,727,278 |
| Open | 255.09 |
| Previous Close | 256.48 |
| Day's Range | 254.99 - 261.61 |
| 52-Week Range | 184.66 - 281.07 |
| Beta | 0.21 |
| Analysts | Buy |
| Price Target | 279.82 (+7.03%) |
| Earnings Date | Oct 13, 2026 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $279.82, which is an increase of 7.03% from the latest price.
News
Wells Fargo, Bank of America, Domino's, Johnson & Johnson, Inflation Data, and More to Watch This Week
Big bank earnings arrive, with Citi, Goldman Sachs, JPMorgan Chase, and more reporting. Consumer and producer price indexes and existing home sales data will provide a read on the economy.
Johnson & Johnson reports new two-year results from Phase 3 ICONIC-LEAD study
Johnson & Johnson announced new two-year results from the Phase 3 ICONIC-LEAD study evaluating ICOTYDE, the first and only targeted oral peptide that precisely blocks the IL-23 receptor, in adults…
New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
Phase 3 data presented at Fall Clinical Dermatology show high, sustained response rates in adults and adolescents, with nearly three-quarters achieving clear or almost clear skin at two years and a co...
Johnson & Johnson price target raised to $282 from $278 at BofA
BofA raised the firm’s price target on Johnson & Johnson to $282 from $278 and keeps a Neutral rating on the shares as part of the firm’s Q3 EPS preview…
Johnson & Johnson price target raised to $290 from $287 at RBC Capital
RBC Capital analyst Trung Huynh raised the firm’s price target on Johnson & Johnson to $290 from $287 and keeps an Outperform rating on the shares. The firm notes that…
Johnson & Johnson price target raised to $303 from $298 at Citi
Citi raised the firm’s price target on Johnson & Johnson to $303 from $298 and keeps a Buy rating on the shares. The firm adjusted targets in the medical technology…
Johnson & Johnson announces two-year data from Phase 3 ICONIC-TOTAL study
Johnson & Johnson announced new two-year data from the Phase 3 ICONIC-TOTAL study demonstrating the positive impact of ICOTYDE on high-impact plaque psoriasis sites. ICOTYDE is the first and only…
Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
Revolutionary IL-23R targeted oral peptide delivers sustained skin clearance and a favorable safety profile in patients with psoriasis affecting sensitive, highly visible areas of the body 60% of pati...
New Global Survey by Johnson & Johnson Finds Most Women Don't Connect Eye Health Changes with Menopause
JACKSONVILLE, Fla.--(BUSINESS WIRE)--New global survey by Johnson & Johnson finds most women don't connect eye health changes with menopause.
Johnson & Johnson’s Imaavy shows efficacy in gMG Phase 2/3 trial
Johnson & Johnson announced new findings on Imaavy – nipocalimab-aahu – for the treatment of generalized myasthenia gravis, or gMG, across 15 novel abstracts to be presented at the 2026…
Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)
New two-year findings from the Phase 2/3 long-term extension demonstrate sustained disease control through two years, improvement in daily function and muscle strength, and reductions in corticosteroi...
Johnson & Johnson price target raised to $285 from $270 at JPMorgan
JPMorgan raised the firm’s price target on Johnson & Johnson to $285 from $270 and keeps a Neutral rating on the shares ahead of the earnings report on October 13.
Johnson & Johnson price target raised to $278 from $263 at BofA
BofA raised the firm’s price target on Johnson & Johnson to $278 from $263 and keeps a Neutral rating on the shares. Following a physician dermatology survey, the firm raised…
Johnson & Johnson says Tremfya met endpoints in Phase 4 STAR study
Johnson & Johnson announced that Tremfya met the primary and major secondary endpoints demonstrating both improvement in axial symptoms and reduction in inflammation by MRI assessment in the Phase 4…
Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study
Topline results show TREMFYA met the primary and major secondary endpoints of axial involvement in PsA - including spinal pain and stiffness - and demonstrated significant improvement in MRI-confirmed...
Johnson & Johnson reports new long-term data from Phase 2 CARTITUDE-2 study
Johnson & Johnson announced new long-term follow-up data from the initial subgroup of cohort A in the Phase 2 CARTITUDE-2 study showing that 50% of patients in early line relapsed…
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
New results suggest earlier treatment may increase the likelihood of long-term remission Study adds to Johnson & Johnson's overwhelming body of evidence supporting its innovative multiple myeloma the...
Johnson & Johnson: Phase 3 MajesTEC-3 study shows ‘sustained’ disease control
Johnson & Johnson announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and survival with TECVAYLI plus DARZALEX FASPRO in patients with relapsed or refractory multipl...
New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma
Analysis shows ~87% of patients treated with TECVAYLI® plus DARZALEX FASPRO® as early as second line were estimated to have comparable mortality risk to the general population A separate analysis show...
J&J's Caplyta meets main goal of bipolar mania study
Johnson & Johnson said on Monday its experimental use of Caplyta for bipolar mania met the main goal of a late-stage study, bringing the drug a step closer to expanding beyond its currently approved...
Johnson & Johnson announces ‘positive’ results from Phase 3 trial of Caplyta
Johnson & Johnson announced positive topline results from the pivotal Phase 3 study evaluating Caplyta for the treatment of manic episodes with or without mixed features in adults with bipolar…
Johnson & Johnson Transcript: Deutsche Bank 2026 Healthcare Summit
The summit highlighted a focus on high-growth markets, robust innovation in oncology and immunology, and a diversified portfolio supporting double-digit growth targets. Med tech and pharma segments are positioned for margin improvement, with disciplined capital allocation and major legal risks resolved.
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
Low rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxis Fewer than 1% of patients discontinued treatment due to treatment-related ...
Contineum, J&J's depression drug fails to meet mid-stage trial goal
Contineum Therapeutics said on Monday an experimental depression drug it developed with Johnson & Johnson failed to meet the main goal of a mid-stage study.
Johnson & Johnson Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The event highlighted a focused portfolio driving accelerated growth, robust pipeline progress, and strategic capital allocation. Advanced therapies in oncology and immunology, new product launches, and MedTech innovation underpin double-digit growth targets through the decade.